Cytogenetic abnormalities commonly associated with B-cell non-Hodgkin lymphomas (NHL) are detected by fluorescence in situ hybridization (FISH). Probes for BCL6 (3q27.3), 6q (6q-/-6), MYC (8q24.21), IGH/CCND1 t(11;14), IGH/BCL2 t(14;18) and MALT1 (18q21) are included in the B-NHL FISH Profile.
Cytogenetic abnormalities commonly associated with high-grade B-cell non-Hodgkin lymphomas (NHL) are detected by fluorescence in situ hybridization (FISH). Probes for BCL6 (3q27.3), IRF4-DUSP22 (6p25.3), MYC (8q24.21), IGH/BCL2 t(14;18)) are included in the B-NHL High-Grade FISH Profile (Enriched). B-cells are enriched from patient’s specimen using immunomagnetic enrichment technology with CD19/CD20 antibodies.
Detects mutations in key genes recurrently mutated in lymphoid malignancies. DNA sequence of targeted regions of the ABL1, ABL2, ALK, ARHGEF1, ARID1A, ARID2, ASXL1, ATM, B2M, BCL2, BCL6, BCOR, BIRC3, BRAF, BTK, CARD11, CCND1, CND2, CCND3, CD274, CD79A, CD79B, CDKN1B, CDKN2A, CDKN2B, CIITA, CREBBP, CRLF2, CSF1R, CTCF, CTNNB1, CXCR4, DDX3X, DIS3, DNMT3A, EBF1, EGR1, EP300, EPOR, ETV6, EZH2, FAM46C, FAS, FAT1, FBXW7, FGFR3, FOXO1, GATA3, GNA13, GNAI2, HIST1H1E, HRAS, ID3, IDH1, IDH2, IKBKB, IKZF1, IKZF3, IRAK4, ITPKB, JAK1, JAK2, JAK3, KLF2, KMT2D, KRAS, MALT1, MAP2K1, MAP3K14, MAPK1, MED12, MEF2B, MYC, MYCN, MYD88, NF1, NFKBIE, NOTCH1, NOTCH2, NOTCH3, NRAS, NT5C2, P2RY8, PDGFRB, PHF6, PIK3CA, PIK3CD, PIK3R1, PIM1, PLCG1, PLCG2, POT1, PPM1D, PRDM1, PRPS1, PTEN, PTPN11, RB1, REL, RHOA, RIPK1, RPS15, RUNX1, S1PR2, SAMHD1, SETD2, SF3B1, SGK1, SH2B3, SOCS1, SPEN, STAT3, STAT5B, STAT6, TBL1XR1, TCF3, TET2, TLR2, TNFAIP3, TNFRSF14, TP53, TRAF2, TRAF3, UBR5, WT1, XPO1, ZFHX4, and ZMYM3 genes is determined using next-generation sequencing (NGS) technology.
DNA sequencing of the amplified IGH gene variable (V) region is performed and is compared to the germline consensus sequence. The mutation status, V region family, and percent difference from germline are reported.
Detects mutations in key genes recurrently mutated in chronic lymphocytic leukemia (CLL) and related lymphoid neoplasms. DNA sequence of targeted regions of the ASXL1, ATM, BCOR, BIRC3, BRAF, BTK, CCND1, CCND2, CDKN2A, CDKN2B, DDX3X, DNMT3A, FAT1, FBXW7, HIST1H1E, IKZF3, IRAK4, ITPKB, KRAS, MAP2K1, MAP3K14, MAPK1, MED12, MEF2B, MYD88, NFKBIE, NOTCH1, NRAS, PLCG2, PIK3CD, POT1, PTEN, RB1, RIPK1, RPS15, SAMHD1, SETD2, SF3B1, SPEN, SPOP, TET2, TLR2, TP53, TRAF2, TRAF3, UBR5, XPO1 and ZMYM3 genes is determined using next-generation sequencing (NGS) technology.
Genoptix, a NeoGenomics Company
2131 Faraday Ave
Carlsbad, CA 92008
Medical Director: Derek Lyle, MD
- NeoGenomics Completes Acquisition of Genoptix, Inc.December 10, 2018 - 9:00 am
- NeoGenomics Signs Definitive Agreement to Acquire GenoptixOctober 23, 2018 - 9:00 am
- Genoptix Launches FDA-Authorized BCR-ABL MRDx® TFR Monitoring Test for Patients with Chronic Myeloid Leukemia on Tasigna® (nilotinib)September 4, 2018 - 8:30 am
HOURS OF OPERATION
Our lab is open six days a week:
5:00am to 6:00pm PT Mon-Fri
7:00am to 3:30pm PT Saturday
For after-hours assistance, your call
will be connected with an on-duty
Client Services Representative.